Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says
Executive Summary
Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.
You may also be interested in...
Thanks Sequester: FDA’s Human Drug Review Costs Decrease To Pre-FY 2011 Level
The agency says human drug review costs were less than $1 billion in fiscal year 2013, the first time that’s happened since FY 2010.
Obama’s FY 2015 Budget Is A Non-Starter, But Is It Still Bad For FDA?
Agency advocates may face stronger headwinds in their efforts to boost FDA funding after presidential budget request comes in nearly flat.
GDUFA: Fee Avoidance Affects Rates Again
Industry avoided application supplement fees by using CBE submissions instead, forcing FDA to change its estimates and sending generic drug user fees higher.